Original Article

Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome

Charles M. van der Horst, M.D., Michael S. Saag, M.D., Gretchen A. Cloud, M.S., Richard J. Hamill, M.D., J. Richard Graybill, M.D., Jack D. Sobel, M.D., Philip C. Johnson, M.D., Carmelita U. Tuazon, M.D., Thomas Kerkering, M.D., Bruce L. Moskovitz, M.D., William G. Powderly, M.D., William E. Dismukes, M.D., and the National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

N Engl J Med 1997; 337:15-21July 3, 1997DOI: 10.1056/NEJM199707033370103

Abstract

Background

Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mortality and low rates of cerebrospinal fluid sterilization.

Full Text of Background...

Methods

In a double-blind multicenter trial we randomly assigned patients with a first episode of AIDS-associated cryptococcal meningitis to treatment with higher-dose amphotericin B (0.7 mg per kilogram per day) with or without flucytosine (100 mg per kilogram per day) for two weeks (step one), followed by eight weeks of treatment with itraconazole (400 mg per day) or fluconazole (400 mg per day) (step two). Treatment was considered successful if cerebrospinal fluid cultures were negative at 2 and 10 weeks or if the patient was clinically stable at 2 weeks and asymptomatic at 10 weeks.

Full Text of Methods...

Results

At two weeks, the cerebrospinal fluid cultures were negative in 60 percent of the 202 patients receiving amphotericin B plus flucytosine and in 51 percent of the 179 receiving amphotericin B alone (P = 0.06). Elevated intracranial pressure was associated with death in 13 of 14 patients during step one. The clinical outcome did not differ significantly between the two groups. Seventy-two percent of the 151 fluconazole recipients and 60 percent of the 155 itraconazole recipients had negative cultures at 10 weeks (95 percent confidence interval for the difference in percentages, -100 to 21). The proportion of patients who had clinical responses was similar with fluconazole (68 percent) and itraconazole (70 percent). Overall mortality was 5.5 percent in the first two weeks and 3.9 percent in the next eight weeks, with no significant difference between the groups. In a multivariate analysis, the addition of flucytosine during the initial two weeks and treatment with fluconazole for the next eight weeks were independently associated with cerebrospinal fluid sterilization.

Full Text of Results...

Conclusions

For the initial treatment of AIDS-associated cryptococcal meningitis, the use of higher-dose amphotericin B plus flucytosine is associated with an increased rate of cerebrospinal fluid sterilization and decreased mortality at two weeks, as compared with regimens used in previous studies. Although consolidation therapy with fluconazole is associated with a higher rate of cerebrospinal fluid sterilization, itraconazole may be a suitable alternative for patients unable to take fluconazole.

Full Text of Discussion...

Read the Full Article...

Media in This Article

Table 1Base-Line Clinical and Laboratory Characteristics of 381 Patients with AIDS-Associated Cryptococcal Meningitis Treated with Amphotericin B plus Flucytosine or Amphotericin B Alone (Step One).

Table 2Clinical and Laboratory Characteristics of the 306 Patients Randomly Assigned to Consolidation Therapy with Fluconazole or Itraconazole (Step Two).

Article Activity

258 articles have cited this article

Article

Cryptococcosis is the most common life-threatening fungal infection in patients infected with the human immunodeficiency virus (HIV).1 Before the epidemic of the acquired immunodeficiency syndrome (AIDS), the standard therapy for cryptococcal meningitis was amphotericin B (0.3 mg per kilogram of body weight per day) and flucytosine (150 mg per kilogram per day) for four to six weeks.2,3 However, the use of flucytosine in patients with AIDS has been controversial. In one large retrospective study, the addition of flucytosine to amphotericin B was associated with significant toxicity and offered no benefit over amphotericin B alone.4

The oral triazole antifungal drugs, fluconazole and itraconazole, are alternatives to amphotericin B, but there are conflicting data on the efficacy of these drugs. The largest prospective study of AIDS-associated cryptococcal meningitis found no difference in outcome between treatment with amphotericin B (0.4 mg per kilogram per day) and treatment with fluconazole, with negative cerebrospinal fluid cultures in less than 50 percent of the patients.5 Overall mortality was 14 percent in the amphotericin B group and 18 percent in the fluconazole group; mortality at two weeks was 8 percent and 15 percent, respectively. The results of smaller studies suggest that amphotericin B given in a higher dose (0.7 or 0.8 mg per kilogram per day), either alone or in combination with flucytosine (100 mg per kilogram per day), may be superior to an oral triazole.6,7 Thus, questions persist about the optimal initial therapy for AIDS-associated cryptococcal meningitis.

The Mycoses Study Group and the AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases designed a multicenter, randomized, double-blind trial to determine the effectiveness of 14 days of higher-dose amphotericin B, with or without flucytosine, as induction therapy in patients with cryptococcal meningitis and to compare fluconazole and itraconazole as consolidation therapy for an additional 8 weeks in patients whose clinical condition had not deteriorated during the induction phase.

Methods

Study Design

The study was conducted in two steps. In step one, patients with a first episode of AIDS-associated cryptococcal meningitis were randomly assigned to receive amphotericin B (0.7 mg per kilogram per day) with either flucytosine (100 mg per kilogram per day in four divided doses) or placebo for the initial two weeks of therapy. In step two, patients whose condition was stable or improved at the completion of step one were randomly assigned, in a double-blind, placebo-controlled fashion, to consolidation therapy with either fluconazole (a loading dose of 800 mg per day for two days, followed by 400 mg per day for eight weeks) or itraconazole (a loading dose of 600 mg per day for three days, followed by 200 mg twice each day for eight weeks). The study protocol was reviewed and approved by the institutional review board at each study site. All patients provided written informed consent.

Study Population

The criteria for enrollment in step one of the study included HIV infection documented by a positive test for HIV antibody or a previous AIDS-defining opportunistic infection, an age of 13 years or older, and a first episode of cryptococcal meningitis documented by a cerebrospinal fluid culture that was positive for Cryptococcus neoformans. Patients were excluded if they had already received a total dose of more than 1 mg of amphotericin B per kilogram or more than 1200 mg of fluconazole, itraconazole, or ketoconazole as treatment for this episode of meningitis. Patients were also excluded if they were comatose; were taking medications that affect the metabolism of itraconazole (e.g., phenytoin, carbamazepine, phenobarbital, or rifamycins) or decrease the absorption of itraconazole (histamine H₂ blockers); were receiving 50 mg or more of hydrocortisone daily; were pregnant or lactating; were unable to take medications by mouth or nasogastric tube; had a history of active hepatitis or moderate-to-severe hematologic, renal, or hepatic dysfunction; or had another acute opportunistic infection requiring therapy during the first two weeks. At the time of the base-line randomization, the patients were stratified according to their mental status (normal, defined as awake and alert, or abnormal, defined as somnolent or obtunded) and the institution at which they were receiving treatment.

The eligibility criteria for step two were a stable or improved clinical condition during the previous 14 days, receipt of a minimal total dose of 7.5 mg of amphotericin B per kilogram, the ability to take oral medications, and hepatic enzyme values that remained lower than 10 times the upper limit of normal and serum bilirubin values that remained lower than 2 times the upper limit of normal. The patients were stratified according to their base-line mental status and the therapy received during step one.

Evaluation

Clinical and laboratory evaluations were performed at base line, twice weekly for the first 2 weeks, weekly for the next 2 weeks, and then every 2 weeks until the 10-week study period was completed. Studies of cerebrospinal fluid and tests of serum cryptococcal antigen were performed at base line and weeks 2, 4, and 10. The Mini–Mental State Examination was performed at base line and weeks 2 and 10.8

Outcomes

Mycologic and clinical outcomes were evaluated separately and together as a composite outcome. At two weeks, the mycologic outcome was considered to be successful if the cerebrospinal fluid fungal culture was negative, and the clinical outcome was considered to be successful if fever, headache, and meningismus were improved or no worse. Successful treatment at 10 weeks was defined mycologically as a negative cerebrospinal fluid fungal culture and clinically as the absence of fever, headache, and meningismus. Toxicity was defined according to the ACTG scale for reporting adverse events.

Statistical Analysis

For both steps, there were two primary evaluations of the outcome: mycologic and clinical. For step one, we assumed that amphotericin B alone would result in cerebrospinal fluid sterilization or clinical stabilization in 20 percent of the patients.5 With a two-sided test, an alpha level of 0.05, and a power of 80 percent to detect a true difference of 20 percent in the mycologic outcome at two weeks in the two groups, the analysis would require 182 patients per group.

For step two, our null hypothesis was that the success rate for fluconazole was at least 15 percent higher than that for itraconazole in terms of both clinical and mycologic outcomes. We wanted to determine whether an analysis of our data would reject this hypothesis in favor of the alternative, that the two triazoles were equally effective. If the true success rate for each triazole were 34 percent, an analysis using a one-sided test with an alpha level of 0.025 and a power of 80 percent to detect a difference would require 157 patients per group, for a total of 314 patients.9 On the basis of an earlier study, we estimated that 20 percent of patients would not be available for random assignment in step two5; consequently, we planned to enroll 400 patients in step one.

The outcome analysis was performed on an intention-to-treat basis. In the case of patients who were not available for a lumbar puncture or evaluation of clinical status at week 2 or 10, treatment was considered to have failed. In the case of patients who died, elevated intracranial pressure was considered to be associated with death if the last known cerebrospinal fluid opening pressure was 250 mm or higher within two weeks before death or if there was no pressure measurement available and the patient had cranial-nerve or other central nervous system findings consistent with elevated pressure or herniation.

The treatment groups were compared by the Kruskal–Wallis test for ordinal measurements and the chi-square test for categorical measurements.10 The Kaplan–Meier method was used in survival analyses, and the treatment groups were compared by the log-rank test.11 The logistic-regression model was used for multivariate assessment of the relative risk of mycologic failure during therapy, after adjustment for potentially confounding factors.12 Base-line data associated with successful outcomes at 2 and 10 weeks (P<0.30) in univariate analyses were included in the multivariate models. Cerebrospinal fluid opening pressure was not included in the multivariate model because of the large number of missing data.

Results

Study Population

From October 1991 through August 1994, 408 patients were enrolled in step one of the study. Twenty-seven of these patients were ineligible at base line (19 had negative cerebrospinal fluid cultures, 4 were receiving corticosteroids or rifampin, 2 had had a previous episode of cryptococcal disease, 1 was HIV-negative, and 1 was pregnant). Of the 381 eligible patients, 202 received amphotericin B plus flucytosine and 179 received amphotericin B alone. Demographic characteristics and base-line laboratory values, CD4 lymphocyte counts, and clinical signs and symptoms of cryptococcal disease did not differ significantly between the two groups (Table 1Table 1Base-Line Clinical and Laboratory Characteristics of 381 Patients with AIDS-Associated Cryptococcal Meningitis Treated with Amphotericin B plus Flucytosine or Amphotericin B Alone (Step One).). Eighty-nine percent of the patients were judged to be awake and alert; however, there were behavioral changes in 21 percent.

A total of 306 patients were eligible for randomization in the second step of the study: 151 received fluconazole and 155 received itraconazole. There were no differences between these two treatment groups at the time of the base-line assessments in step two (Table 2Table 2Clinical and Laboratory Characteristics of the 306 Patients Randomly Assigned to Consolidation Therapy with Fluconazole or Itraconazole (Step Two).). Seventy-five patients were not randomly assigned to a treatment group in step two: 19 died while receiving therapy in step one; 11 had a deterioration in clinical status; 11 had toxic effects necessitating discontinuation of the study drug; 7 were receiving antiepileptic agents, rifampin, or H₂ blockers; 4 had concurrent acute opportunistic infections; 1 did not receive an adequate total dose of amphotericin B; 1 was not alert enough to take oral medications; and 21 withdrew from the study or were lost to follow-up.

Outcomes

Step One

As shown in Table 3Table 3Outcome at Two Weeks (Step One)., at two weeks, cerebrospinal fluid cultures were negative in 60 percent of the patients who received amphotericin B with flucytosine and in 51 percent of those who received amphotericin B alone (P = 0.06). There were no significant differences in the proportions of patients with stable or improved symptoms (78 percent of the combination-therapy group and 83 percent of the amphotericin B group, P = 0.18), unchanged or improved scores on the Mini–Mental State Examination (77 percent of the combination-therapy group and 74 percent of the amphotericin B group, P = 0.42), or combined mycologic and clinical responses (50 percent of the combination-therapy group and 42 percent of the amphotericin B group, P = 0.12). Over the two-week period, the median titer of cerebrospinal fluid cryptococcal antigen declined from 1:1024 at base line in both treatment groups to 1:200 in the combination-therapy group and 1:256 in the amphotericin B group (P = 0.56).

Step Two

At 10 weeks, 72 percent of the patients receiving fluconazole had negative cerebrospinal fluid cultures; lumbar punctures were not performed in 39 patients (Table 4Table 4Outcome at 10 Weeks (Step Two).). In the itraconazole group, cerebrospinal fluid cultures were negative in 60 percent of the patients; 54 patients did not have lumbar punctures (95 percent confidence interval for the difference between the percentages of patients with negative cultures in the two groups, -100 to 21). Therefore, we were unable to reject the null hypothesis that fluconazole was 15 percent more effective than itraconazole in terms of the sterilization of cerebrospinal fluid cultures.

With regard to clinical efficacy, 68 percent of the fluconazole recipients and 70 percent of the itraconazole recipients had complete resolution of symptoms (headache, fever, and meningismus). On the Mini–Mental State Examination, 68 percent of the fluconazole recipients and 70 percent of the itraconazole recipients had unchanged or improved scores. Thus, in terms of clinical success, there was no significant difference between the treatment groups, and the null hypothesis that the clinical efficacy of fluconazole was 15 percent greater than that of itraconazole was rejected.

Over the eight-week period of consolidation therapy, the median titer of cerebrospinal fluid cryptococcal antigen declined in both treatment groups, from 1:256 in both groups at 2 weeks to 1:57 in the fluconazole group and 1:32 in the itraconazole group at 10 weeks (P = 0.22). The four treatment combinations did not differ significantly with regard to cerebrospinal fluid culture sterilization, resolution of clinical symptoms, or survival at 10 weeks (data not shown).

Deaths

During step one, 21 patients died (5.5 percent): 11 of the 202 patients in the amphotericin B group and 10 of the 179 in the combination-treatment group (P = 0.65 by the log-rank test). During step two, there were 2 deaths among the 151 fluconazole recipients and 5 among the 155 itraconazole recipients; an additional 2 fluconazole recipients and 3 itraconazole recipients died during weeks 3 to 10 but were not receiving the study drug at the time (P = 0.27, by the log-rank test, for total deaths). Thus, 12 of the 306 patients (3.9 percent) in step two died. Seven other patients who had been enrolled in step one but were not randomly assigned to treatment in step two died during weeks 3 to 10.

Cerebrospinal Fluid Opening Pressure

During step one, the median base-line cerebrospinal fluid opening pressure was 220 mm in the 123 patients with negative cerebrospinal fluid cultures at two weeks and 280 mm in the 97 with persistently positive cultures (P = 0.01). Of the 14 patients who died and for whom cerebrospinal fluid opening pressures were determined, 13 had pressures higher than 250 mm at the time of the last lumbar puncture. Six of these patients also had cranial-nerve abnormalities or palsies, ataxia, or herniation. Two patients in whom opening pressures were not measured had ataxia or a clinical diagnosis of elevated intracranial hypertension; both patients died.

Factors Predicting Outcome

We performed a multivariate analysis of base-line characteristics associated with a negative cerebrospinal fluid culture at 2 weeks and at 10 weeks (Table 5Table 5Multivariate Analysis of Base-Line Characteristics Associated with Negative Cerebrospinal Fluid Cultures at 2 and 10 Weeks.). Data were available for 268 patients at 2 weeks and 306 patients at 10 weeks. An elevated base-line serum creatinine value (P = 0.04), treatment with amphotericin B plus flucytosine (P = 0.01), the presence of fever (P = 0.02), and a negative blood culture for C. neoformans (P = 0.001) were independently associated with a negative cerebrospinal fluid culture at two weeks. Factors significantly associated with a negative culture at 10 weeks, after adjustment for the covariate of time, were the absence of intravenous drug use (P = 0.03), fluconazole therapy (P = 0.02; odds ratio, 1.78), and a negative cerebrospinal fluid culture at 2 weeks (P = 0.01). A multivariate logistic-regression analysis showed that the study treatment was not associated with a clinical benefit at 2 or 10 weeks.

Drug Toxicity

Step One

Eleven patients (2.9 percent) had toxic effects requiring the withdrawal of the study drug (six receiving combination therapy and five receiving amphotericin B alone). Three patients had elevated serum creatinine values, two had nausea, two had hypokalemia, and one each had a rash, headache, hemolytic anemia, and a gastrointestinal hemorrhage. Overall, there were no differences in toxic effects between the treatment groups, regardless of whether the base-line hematologic values were normal or abnormal. Among the patients with normal serum creatinine values at base line, 1 percent in each group had values that were more than three times the upper limit of normal during the two weeks of treatment.

Step Two

During step two, 12 patients (6 in each group) had toxic effects requiring the withdrawal of the study drug. Six patients had nausea and vomiting, two of whom had elevated serum creatinine values. Two patients had rashes, including one patient receiving fluconazole, who had the Stevens–Johnson syndrome and survived. One patient each had hyperkalemia, headache, neutropenia, and hepatic failure. Two of these patients died (the patient with hepatic failure and the patient with hyperkalemia); both were in the itraconazole group. Overall, 28 percent of the patients had hematologic toxic effects, 7 percent had hepatic toxic effects, and 4 percent had renal toxic effects.

Discussion

This study was designed to address a number of critical questions in the management of AIDS-associated cryptococcal meningitis: Does the addition of flucytosine offer any advantage over amphotericin B alone? Are the triazole antifungal drugs, fluconazole and itraconazole, equally effective after initial treatment with amphotericin B? Do higher doses of amphotericin B lead to a reduction in the mortality rates reported in previous studies (14 to 18 percent)?

Both in vivo and in vitro data suggest that flucytosine has at least an additive effect, if not a synergistic effect, when combined with amphotericin B.13,14 In the era before AIDS, the combination regimen of flucytosine (150 mg per kilogram per day) and low-dose amphotericin B (0.3 mg per kilogram per day) for 6 weeks was equivalent to or better than amphotericin B alone (0.4 mg per kilogram per day) for 10 weeks, with regard to cures, relapses, and rates of cerebrospinal fluid sterilization.2 In contrast, among patients with AIDS and cryptococcal disease evaluated retrospectively, the combination of flucytosine (75 to 100 mg per kilogram per day) and amphotericin B did not alter survival, as compared with amphotericin B alone; in addition, in 53 percent of the patients receiving combination therapy, flucytosine had to be withdrawn because of drug-associated cytopenias.4 A small study showed that treatment with higher doses of amphotericin B (0.7 mg per kilogram per day) combined with flucytosine (150 mg per kilogram per day) was dramatically successful.15

In our study, the addition of lower-dose flucytosine (100 mg per kilogram per day) to amphotericin B for the first two weeks of therapy was not associated with a statistically significant benefit in the univariate analysis, although the rate of cerebrospinal fluid sterilization was higher with the combination regimen than with amphotericin B alone. The addition of flucytosine was independently associated with a better outcome in the multivariate analysis. Moreover, in our study, the addition of flucytosine to amphotericin B was not associated with an increased incidence of toxic effects, probably because of the shorter duration of flucytosine therapy and the use of a daily dose lower than those in a previous study.4

For the consolidation phase (step two), we were unable to reject the null hypothesis that fluconazole was 15 percent more effective than itraconazole in terms of cerebrospinal fluid sterilization. The multivariate analysis showed a significant association between fluconazole therapy and negative cultures at 10 weeks. The clinical efficacy of fluconazole and itraconazole was similar with respect to the resolution of symptoms, scores on the Mini–Mental State Examination, and the mortality rate.

One possible reason for the different culture results in the two groups in step two is the difference in the number of patients who did not have lumbar punctures at 10 weeks (54 of the 155 itraconazole recipients vs. 39 of the 151 fluconazole recipients), since the mycologic outcome in these patients was considered to be unsuccessful. Among the study participants who underwent lumbar punctures at week 10, the cerebrospinal fluid culture was negative in 97 percent of those receiving fluconazole (109 of 112) and in 92 percent of those receiving itraconazole (93 of 101). Just as we found that fluconazole resulted in a higher rate of cerebrospinal fluid sterilization than itraconazole, a separate study comparing a lower dose of fluconazole (200 mg per day) with itraconazole (200 mg per day) has clearly shown that fluconazole is superior as maintenance therapy in suppressing cryptococcal infection.16

Mortality rates for AIDS-associated acute cryptococcal meningitis have ranged from 14 percent among patients receiving amphotericin B alone in our most recent trial to over 25 percent in some trials of azoles as initial therapy.5,17 Most of the deaths occurred during the first two weeks of therapy. Thus, to our knowledge, the mortality rates in our current study (5.5 percent in the first two weeks and 3.9 percent in the next eight weeks) represent the best outcome reported thus far in a large, randomized trial.

The higher dose of amphotericin B in our study (0.7 mg per kilogram per day), with or without flucytosine, may account, in large part, for the low mortality rate. The increased dose of amphotericin B also resulted in a 50 percent rate of cerebrospinal fluid sterilization at two weeks without significant toxicity, which is substantially better than the 20 percent sterilization rate reported in our previous large study of AIDS-associated cryptococcal meningitis, in which the dose of amphotericin B was 0.4 mg per kilogram per day.5 We believe these two studies are comparable, since the patients in the previous study had similar base-line characteristics, including positive blood cultures in 53 percent, abnormal mental status in 27 percent, and a median cerebrospinal fluid white-cell count of 5 cells per cubic millimeter. The patients in the previous study had lower median titers of cryptococcal antigen in serum (1:1000, P<0.001) and in cerebrospinal fluid (1:512, P<0.001) at base line and thus presumably had a lower fungal burden. In a recent study, an even higher dose of amphotericin B (1 mg per kilogram per day), with or without flucytosine, for two weeks, followed by fluconazole or itraconazole, resulted in a successful outcome in 29 of 31 patients (94 percent), with no deaths due to cryptococcal disease.18

Careful management of elevated intracranial pressure is another important factor that probably played a part in the improved outcome in this study. High pressures have been associated with catastrophic neurologic deterioration and death in the absence of hydrocephalus.19 Almost all the early deaths in this study (13 of 14) and 40 percent of the deaths during weeks 3 through 10 were associated with elevated intracranial pressure. Our study protocol included a treatment algorithm for the management of increased pressure, including daily lumbar punctures, use of acetazolamide, and ventriculoperitoneal shunts for asymptomatic patients with intracranial cerebrospinal fluid pressures higher than 320 mm and for symptomatic patients with pressures higher than 180 mm. Further research is needed to examine this association and determine whether a reduction of high pressure can, in fact, decrease mortality.

In summary, induction treatment for two weeks with the combination regimen of higher-dose amphotericin B plus flucytosine, followed by consolidation therapy with oral fluconazole, is safe and effective and should now be considered the treatment of choice for AIDS-associated cryptococcal meningitis. In view of the positive influence of flucytosine therapy on the mycologic outcome (in our multivariate analysis), its low degree of toxicity in our study, and recent data demonstrating its effectiveness in preventing relapses (regardless of the maintenance regimen), we believe that the addition of flucytosine to amphotericin B is warranted for induction therapy.16 For consolidation therapy, itraconazole is a suitable alternative for patients unable to take fluconazole. The strong association between elevated intracranial pressure and early death in our study should encourage clinicians to monitor cerebrospinal fluid pressure even in the absence of symptoms and initiate aggressive management if the pressure is elevated.

Presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995.

Supported by grants from the National Institute of Allergy and Infectious Diseases to the Mycoses Study Group (NO1-AI-15082 and NO1-AI-65296) and the AIDS Clinical Trials Group and by grants from the National Center for Research Services and the Janssen Research Foundation. The drugs for the study were provided by Bristol-Myers Squibb (amphotericin B), Roche Laboratories (flucytosine), Roerig–Pfizer (fluconazole), and the Janssen Research Foundation (itraconazole).

We are indebted to the numerous referring physicians and to the 408 patients whose participation made this study possible. We dedicate this paper to them.

Source Information

From the Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (C.M.H.); the Division of Infectious Diseases, Department of Medicine (M.S.S., W.E.D.), and the Biostatistics Unit, Comprehensive Cancer Center (G.A.C.), University of Alabama School of Medicine at Birmingham, Birmingham; the Section of Infectious Diseases, Veterans Affairs Medical Center and Baylor College of Medicine, Houston (R.J.H.); the University of Texas Health Sciences Center, San Antonio (J.R.G.); the Division of Infectious Diseases, Wayne State University, Detroit (J.D.S.); the Department of Medicine, University of Texas–Houston Medical Center, Houston (P.C.J.); the Department of Medicine, George Washington University, Washington, D.C. (C.U.T.); the Division of Infectious Diseases, Medical College of Virginia, Richmond (T.K.); the Janssen Research Foundation, Titusville, N.J. (B.L.M.); and the Division of Infectious Diseases, Washington University School of Medicine, St. Louis (W.G.P.).

Address reprint requests to Dr. van der Horst at the Division of Infectious Diseases, C.B.# 7030, University of North Carolina, Chapel Hill, NC 27599-7030.

Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group are listed in the Appendix.

Appendix

The following institutions and investigators contributed to the study: Mycoses Study Group: Operations Office, Birmingham, Ala. — L. Riser and C. Thomas; Veterans Affairs Medical Center and Baylor College of Medicine — C. Lacke and A.C. White; University of Alabama at Birmingham — S. Patterson, D. Davis, and C. Flanigan; University of Texas at San Antonio — T. Harden and D. Phillips; Detroit Medical Center — L. Ullom and J. Vasquez; George Washington University Medical Center — S. McMullen; University of Texas, Houston — D. Flowers and M. Bosha; Medical College of Virginia — M. Britton; Medical College of Georgia — J.F. Fisher, C. Newman, and B. Willis; University of Mississippi Medical Center — H. Henderson; St. Michael's Medical Center — E. Johnson and L. Dungo; Vanderbilt University — M. Pierce and M. Morgan; Pennsylvania Hospital — J. Stern and N. Petrosky; University of Missouri, Kansas City — D. Bamberger and R. Farnan; Johns Hopkins University — J. Feinberg, L. Apuzzo, and W. Royal; Emory University — S. Thompson and K. Barrett; University of Michigan — C. Kauffman and H. Gutsch; Infectious Diseases Associates of Kansas City — D. McKinsey and B. Lee; Tulane University — N. Hyslop, D. Greenspan, and R. Strata; Permanente Medical Group — W.J. Fessel and G. Van Raalte; and the Ochsner Clinic — G. Pankey.

AIDS Clinical Trials Group: Data Center, Frontier Sciences and Technology Research Foundation, Amherst, N.Y. — D. Schneider; Operations Office, Social and Scientific Systems, Bethesda, Md. — N.D. Briggs and D. Pierce; University of North Carolina at Chapel Hill — S. Lee, I. Vangness, and B. Longmire; University of California at San Francisco — J. Stansell, M. Jacobson, D. Gray, and R. Coleman; Washington University — J. Voorhees, M. Klebert, and M. Royal; Beth Israel Medical Center — D. Mildvan; Yale University — G. Friedland, E. Cooney, and M. Walesky; University of Southern California — J.M. Leedom, R. Larsen, and D. Diamond; Indiana University — L.J. Wheat, H. Nixon, and J. Craft; Ohio State University — J.L. Neidig, R.J. Fass, and J. Russell; University of Pennsylvania — R.R. MacGregor, R. Kappes, and A. Tselis; University of Cincinnati — K.J. Skahan, B. Jackson, P. Daniel, and C. Paulson-White; University of Rochester — R. Hewitt, S. Cohn, M. Lewis, and C. Greisberger; Harvard University — H. Heller, A. Sugar, A.W. Karchmer, and H. Fitch; Harlem Hospital Center — R. Flam, M. Joseph, and W. El-Sadr; University of Massachusetts — S.H. Cheeseman, K.K. Lai, and M. Sands; Albert Einstein College of Medicine — R. Soeiro, D. Stein, and B. Zingman; University of Texas, Galveston — R. Pollard, S. Hausrath, and K. Waterman; Cornell University — K. Squires and L. Ponticello; and St. Luke's–Roosevelt Medical Center — M. Grieco.

National Institute of Allergy and Infectious Diseases: R. Hafner and D. Dixon.

References

References

1. 1

   Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837-842
   CrossRef | Web of Science | Medline

2. 2

   Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-131
   Full Text | Web of Science | Medline

3. 3

   Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-341
   Full Text | Web of Science | Medline

4. 4

   Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-799
   Full Text | Web of Science | Medline

5. 5

   Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-89
   Free Full Text | Web of Science | Medline

6. 6

   Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-745
   CrossRef | Web of Science | Medline

7. 7

   de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-190
   CrossRef | Web of Science | Medline

8. 8

   Folstein MF, Folstein SE, McHugh PR. “Mini-mental state“: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
   CrossRef | Web of Science | Medline

9. 9

   Blackwelder WC. “Proving the null hypothesis“ in clinical trials. Control Clin Trials 1982;3:345-353
   CrossRef | Medline

10. 10

    Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames: Iowa State University Press, 1967.
    

11. 11

    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
    CrossRef | Web of Science

12. 12

    Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989.
    

13. 13

    Medoff G, Comfort M, Kobayashi GS. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med 1971;138:571-574
    Web of Science | Medline

14. 14

    Block ER, Bennett JE. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Biol Med 1973;142:476-480
    Web of Science | Medline

15. 15

    Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113:183-187
    Web of Science | Medline

16. 16

    Saag MS, Cloud GA, Graybill JR, et al. Comparison of fluconazole versus itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995. Washington, D.C.: American Society for Microbiology, 1995.
    

17. 17

    Moskovitz BL, Wiesinger B, Cryptococcal Meningitis Research Group. Randomized, comparative study of itraconazole and fluconazole for treatment of AIDS-related cryptococcal meningitis. In: Proceedings of the First National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12–16, 1993. abstract.
    

18. 18

    de Lalla F, Pellizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-266
    CrossRef | Web of Science | Medline

19. 19

    Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91:267-272
    CrossRef | Web of Science | Medline

Citing Articles (258)

Citing Articles

1. 1

   Angela Loyse, Harry Thangaraj, Philippa Easterbrook, Nathan Ford, Monika Roy, Tom Chiller, Nelesh Govender, Thomas S Harrison, Tihana Bicanic. (2013) Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. The Lancet Infectious Diseases
   

2. 2

   Ana-Claire Meyer, Mark Jacobson. (2013) Asymptomatic Cryptococcemia in Resource-Limited Settings. Current HIV/AIDS Reports
   

3. 3

   Jodi Lestner, William W Hope. (2013) Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opinion on Drug Metabolism & Toxicology1-16
   

4. 4

   Ricardo M. La Hoz, Peter G. Pappas. (2013) Cryptococcal Infections: Changing Epidemiology and Implications for Therapy. Drugs 73:6, 495-504
   

5. 5

   Perfect , John R. , . (2013) Efficiently Killing a Sugar-Coated Yeast. New England Journal of Medicine 368:14, 1354-1356
   Full Text

6. 6

   Day , Jeremy N. , Chau , Tran T.H. , Wolbers , Marcel , Mai , Pham P. , Dung , Nguyen T. , Mai , Nguyen H. , Phu , Nguyen H. , Nghia , Ho D. , Phong , Nguyen D. , Thai , Cao Q. , Thai , Le H. , Chuong , Ly V. , Sinh , Dinh X. , Duong , Van A. , Hoang , Thu N. , Diep , Pham T. , Campbell , James I. , Sieu , Tran P.M. , Baker , Stephen G. , Chau , Nguyen V.V. , Hien , Tran T. , Lalloo , David G. , Farrar , Jeremy J. , . (2013) Combination Antifungal Therapy for Cryptococcal Meningitis. New England Journal of Medicine 368:14, 1291-1302
   Full Text

7. 7

   G. P. Bisson, M. Molefi, S. Bellamy, R. Thakur, A. Steenhoff, N. Tamuhla, T. Rantleru, I. Tsimako, S. Gluckman, S. Ravimohan, D. Weissman, P. Tebas. (2013) Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis. Clinical Infectious Diseases
   

8. 8

   Sheel Patel, Gee Yen Shin, Ishan Wijewardana, Sasiri Rivinda Vitharana, Ian Cormack, Mark Pakianathan, Thomas S. Harrison, Tihana Bicanic. (2013) The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. Journal of Infection 66:1, 75-79
   

9. 9

   Jun Yong Choi. (2013) Common Infectious Diseases in HIV Infected Persons. Korean Journal of Medicine 84:2, 179
   

10. 10

    Spinello Antinori. (2013) New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS 2013, 1-22
    

11. 11

    Russell E. Lewis, Pierluigi Viale. (2012) Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses. Current Fungal Infection Reports 6:4, 349-357
    

12. 12

    John R. Graybill. (2012) Combination Antifungal Therapy: Is it for everyone and every mycosis?. Infectio 16, 11-22
    

13. 13

    Jairo Lizarazo, Elizabeth Castañeda. (2012) Consideraciones sobre la criptococosis en los pacientes con sida. Infectio 16, 94-99
    

14. 14

    Arthur Jackson, Charles Horst. (2012) New Insights in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis. Current HIV/AIDS Reports 9:3, 267-277
    

15. 15

    Chia-Hung Liao, Chih-Yu Chi, Yi-Jen Wang, Shu-Wen Tseng, Chia-Huei Chou, Cheng-Mao Ho, Po-Chang Lin, Mao-Wang Ho, Jen-Hsian Wang. (2012) Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis. Journal of Microbiology, Immunology and Infection 45:4, 296-304
    

16. 16

    Stefan Schwartz. (2012) Bildgebende Diagnostikverfahren und Therapieoptionen bei zerebralen Aspergillosen. Mycoses 55, 10-16
    

17. 17

    Csaba Somlai, Estela Correche, Monica Olivella, Laia Tolosa, Maria José Gomez Lechon, György Dombi, Gábor K. Tóth, Botond Penke, Ricardo D. Enriz. (2012) Synthesis and cytotoxic activity of 4-N-carboxybutyl-5-fluorocytosyl-Arg-Gln-Trp-Arg-Arg-Trp-Trp-Gln-Arg-NH2. Bioorganic & Medicinal Chemistry Letters 22:13, 4233-4237
    

18. 18

    Ik Lin Tan, Bryan R Smith, Gloria von Geldern, Farrah J Mateen, Justin C McArthur. (2012) HIV-associated opportunistic infections of the CNS. The Lancet Neurology 11:7, 605-617
    

19. 19

    Senthil K. Sivalingam, Pragathi Saligram, Sivakumar Natanasabapathy, Armando S. Paez. (2012) Covert Cryptococcal Meningitis in a Patient With Systemic Lupus Erythematous. The Journal of Emergency Medicine 42:5, e101-e104
    

20. 20

    A. Jackson, J. Nussbaum, J. Phulusa, D. Namarika, M. Chikasema, C. Kenyemba, J.N. Jarvis, S. Jaffar, M.C. Hosseinipour, C. van der Horst, T.S. Harrison. (2012) A phase II randomised controlled trial adding oral flucytosine to high dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis in Malawi. AIDS1
    

21. 21

    (2012) Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-infected Koreans. Infection & Chemotherapy 44:3, 93
    

22. 22

    Kathleen R. Page, Richard E. Chaisson, Merle Sande. Cryptococcosis and other fungal infections (histoplasmosis and coccidioidomycosis) in HIV-infected patients. In: Sande's HIV/AIDS Medicine. Elsevier, 2012:369-388.
    

23. 23

    Monika Roy, Tom M. Chiller. (2011) Preventing Death from HIV-Associated Cryptococcal Meningitis: The Way Forward. Current Fungal Infection Reports 5:4, 206-214
    

24. 24

    J. Bennett. (2011) Companion Drugs for Amphotericin B in Cryptococcal Meningitis: Flucytosine, Fluconazole, or...Nothing?. Clinical Infectious Diseases
    

25. 25

    M Nelson, H Manji, E Wilkins. (2011) 2 Central nervous system opportunistic infections. HIV Medicine 12, 8-24
    

26. 26

    R. Timothy Bentley, Dominik Faissler, James Sutherland-Smith. (2011) Successful management of an intracranial phaeohyphomycotic fungal granuloma in a dog. Journal of the American Veterinary Medical Association 239:4, 480-485
    

27. 27

    Michael E. Klepser. (2011) Optimizing Amphotericin B Therapy for Cryptococcal Meningitis. Current Fungal Infection Reports 5:2, 57-58
    

28. 28

    Xing-Cong Li, K. Suresh Babu, Melissa R. Jacob, Shabana I. Khan, Ameeta K. Agarwal, Alice M. Clark. (2011) Natural Product-Based 6-Hydroxy-2,3,4,6-tetrahydropyrrolo[1,2- a ]pyrimidinium Scaffold as a New Antifungal Template. ACS Medicinal Chemistry Letters 2:5, 391-395
    

29. 29

    José María Aguado, Isabel Ruiz-Camps, Patricia Muñoz, José Mensa, Benito Almirante, Lourdes Vázquez, Montserrat Rovira, Pilar Martín-Dávila, Asunción Moreno, Francisco Álvarez-Lerma, Cristóbal León, Luis Madero, Jesús Ruiz-Contreras, Jesús Fortún, Manuel Cuenca-Estrella. (2011) Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enfermedades Infecciosas y Microbiología Clínica 29:5, 345-361
    

30. 30

    Melanie W. Pound, Mary L. Townsend, Vincent Dimondi, Dustin Wilson, Richard H. Drew. (2011) Overview of treatment options for invasive fungal infections. Medical Mycology1-20
    

31. 31

    S. Yaich, N. El'Aoud, I. Maaloul, K. Charfeddine, M. Kharrat, M. Ben Jemaa, J. Hachicha. (2011) Early Onset of Paucisymptomatic Cryptococcal Meningitis in a Kidney Transplant Patient: A Case Report and Review of the Literature. Transplantation Proceedings 43:2, 663-665
    

32. 32

    Isabel Ruiz-Camps. (2011) Tratamiento combinado de la aspergilosis invasora. ¿Una oportunidad para micafungina?. Enfermedades Infecciosas y Microbiología Clínica 29, 38-42
    

33. 33

    Necdet Kuyucu. (2011) Amphotericin B use in children: conventional and lipid-based formulations. Expert Review of Anti-infective Therapy 9:3, 357-367
    

34. 34

    J. W. Baddley, D. C. Schain, A. A. Gupte, S. A. Lodhi, L. K. Kayler, J. P. Frade, S. R. Lockhart, T. Chiller, J. S. Bynon, W. A. Bower. (2011) Transmission of Cryptococcus neoformans by Organ Transplantation. Clinical Infectious Diseases 52:4, e94-e98
    

35. 35

    Comfort A. Boateng, Suresh V.K. Eyunni, Xue Y. Zhu, Jagan R. Etukala, Barbara A. Bricker, M.K. Ashfaq, Melissa R. Jacob, Shabana I. Khan, Larry A. Walker, Seth Y. Ablordeppey. (2011) Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens. Bioorganic & Medicinal Chemistry 19:1, 458-470
    

36. 36

    Su Jin Lee, Hee Kyoung Choi, Jungmin Son, Kye Hyung Kim, Sun Hee Lee. (2011) Cryptococcal Meningitis in Patients with or without Human Immunodeficiency Virus: Experience in a Tertiary Hospital. Yonsei Medical Journal 52:3, 482
    

37. 37

    Guanggan Hu, Joyce Wang, Jaehyuk Choi, Won Hee Jung, Iris Liu, Anastasia P Litvintseva, Tihana Bicanic, Rajeev Aurora, Thomas G Mitchell, John R Perfect, James W Kronstad. (2011) Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics 12:1, 526
    

38. 38

    Gregory M. Anstead, Tihana Bicanic, Eduardo Arathoon, John R. Graybill. Histoplasmosis, Blastomycosis, Coccidioidomycosis, and Cryptococcosis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice. Elsevier, 2011:573-581.
    

39. 39

    Andrew H. Limper, Kenneth S. Knox, George A. Sarosi, Neil M. Ampel, John E. Bennett, Antonino Catanzaro, Scott F. Davies, William E. Dismukes, Chadi A. Hage, Kieren A. Marr, Christopher H. Mody, John R. Perfect, David A. Stevens. (2011) An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients. American Journal of Respiratory and Critical Care Medicine 183:1, 96-128
    

40. 40

    Nikolaos G Almyroudis, Brahm H Segal. (2010) Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Review of Anti-infective Therapy 8:12, 1451-1466
    

41. 41

    Lewis J Haddow, Robert Colebunders, Graeme Meintjes, Stephen D Lawn, Julian H Elliott, Yukari C Manabe, Paul R Bohjanen, Somnuek Sungkanuparph, Philippa J Easterbrook, Martyn A French, David R Boulware. (2010) Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. The Lancet Infectious Diseases 10:11, 791-802
    

42. 42

    P. Portegies, P. Cinque, A. Chaudhuri, J. Begovac, I. Everall, T. Weber, M. Bojar, P. Martinez - Martin, P. G. E. Kennedy. Neurological Complications of HIV Infection. In: European Handbook of Neurological Management. Wiley-Blackwell, 2010:373-381.
    

43. 43

    Peter G. Pappas. (2010) Opportunistic Fungi: A View to the Future. The American Journal of the Medical Sciences 340:3, 253-257
    

44. 44

    Russell E. Lewis. (2010) Antifungal Therapeutic Drug Monitoring. Current Fungal Infection Reports 4:3, 158-167
    

45. 45

    A. H. Groll, A. Tragiannidis. (2010) Update on antifungal agents for paediatric patients. Clinical Microbiology and Infection 16:9, 1343-1353
    

46. 46

    Antonio Chirianni, Vincenzo Esposito. (2010) HIV-related cryptococcal meningitis in resource-limited settings. HIV Therapy 4:5, 567-576
    

47. 47

    Arthur Jackson, Mina C. Hosseinipour. (2010) Management of Cryptococcal Meningitis in Sub-Saharan Africa. Current HIV/AIDS Reports 7:3, 134-142
    

48. 48

    Kyle D. Brizendine, Peter G. Pappas. (2010) Cryptococcal Meningitis: Current Approaches to Management in Patients With and Without AIDS. Current Infectious Disease Reports 12:4, 299-305
    

49. 49

    Allan R. Tunkel. (2010) Clinical Trial Report: Treatment of Cryptococcal Meningitis in the Developing World. Current Infectious Disease Reports 12:4, 234-236
    

50. 50

    Nathan P. Wiederhold. (2010) Using Antifungal Pharmacodynamics to Improve Patient Outcomes. Current Fungal Infection Reports 4:2, 70-77
    

51. 51

    B. Zhai, H. Zhou, L. Yang, J. Zhang, K. Jung, C. Z. Giam, X. Xiang, X. Lin. (2010) Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. Journal of Antimicrobial Chemotherapy 65:5, 931-938
    

52. 52

    John R. Perfect, Gary M. Cox. Cryptococcosis. In: Topley & Wilson's Microbiology and Microbial Infections. John Wiley & Sons, Ltd, 2010.
    

53. 53

    Sanjay G. Revankar, John R. Graybill, Thomas F. Patterson. Antifungal Agents and Antifungal Susceptibility Testing. In: Topley & Wilson's Microbiology and Microbial Infections. John Wiley & Sons, Ltd, 2010.
    

54. 54

    Su Jin Jeong, Yun Tae Chae, Sung Joon Jin, Ji-hyeon Baek, Bum Sik Chin, Sang Hoon Han, Chang Oh Kim, Jun Yong Choi, Young Goo Song, June Myung Kim. (2010) Cryptococcal Meningitis : 12 Years Experience in a Single Tertiary Health Care Center. Infection and Chemotherapy 42:5, 285
    

55. 55

    Hye Ryun Jung, Hyun Hee Kwon, Jung-Yoon Choe. (2010) A Case of Disseminated Crytococcosis in a Patient with Systemic Lupus Erythematosus. The Journal of the Korean Rheumatism Association 17:2, 194
    

56. 56

    ANTIFUNGAL DRUGS. In: Meyler's Side Effects of Antimicrobial Drugs. Elsevier, 2010:647-775.
    

57. 57

    HENRY MASUR. Management of Opportunistic Infections Associated with Human Immunodeficiency Virus Infection. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:1855-1886.
    

58. 58

    JOHN H. REX, DAVID A. STEVENS. Systemic Antifungal Agents. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:549-563.
    

59. 59

    IGOR J. KORALNIK. Neurologic Diseases Caused by Human Immunodeficiency Virus Type 1 and Opportunistic Infections. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:1745-1764.
    

60. 60

    SATISH K. PILLAI, GEORGE M. ELIOPOULOS, ROBERT C. MOELLERING. Principles of Anti-infective Therapy. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:267-278.
    

61. 61

    JOHN R. PERFECT. Cryptococcus neoformans. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:3287-3303.
    

62. 62

    Paula S. Seal, Peter G. Pappas. Systemic fungal infections. In: Antibiotic and Chemotherapy. Elsevier, 2010:777-796.
    

63. 63

    Theresa B. Kim, Steven D. Pletcher, Andrew N. Goldberg. Head and Neck Manifestations in the Immunocompromised Host. In: Cummings Otolaryngology - Head and Neck Surgery. Elsevier, 2010:209-229.
    

64. 64

    P. Germaud, D. Boutoille, F. Gay-Andrieu. (2010) Mycoses bronchopulmonaires (aspects immunoallergiques exclus). EMC - Pneumologie 7:1, 1-26
    

65. 65

    Dustin T. Wilson, Richard H. Drew, John R. Perfect. (2009) Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update. Mycopathologia 168:6, 313-327
    

66. 66

    Richard Drew. Flucytosine. In: Antifungal Therapy. CRC Press, 2009:184-198.
    

67. 67

    Management of Cryptococcosis. In: Antifungal Therapy. CRC Press, 2009:308-319.
    

68. 68

    Richard Drew. Polyenes for Prevention and Treatment of Invasive Fungal Infections. In: Antifungal Therapy. CRC Press, 2009:163-183.
    

69. 69

    Elizabeth Dodds Ashley. Pharmacology of Azole Antifungal Agents. In: Antifungal Therapy. CRC Press, 2009:199-218.
    

70. 70

    A Rizal Ganiem, Ida Parwati, Rudi Wisaksana, Adri van der Zanden, Diederik van de Beek, Patrick Sturm, Andre van der Ven, Bachti Alisjahbana, Anne-Marie Brouwer, Nani Kurniani, Jan de Gans, Reinout van Crevel. (2009) The effect of HIV infection on adult meningitis in Indonesia: a prospective cohort study. AIDS 23:17, 2309-2316
    

71. 71

    Derek J Sloan, Martin J Dedicoat, David G Lalloo. (2009) Treatment of cryptococcal meningitis in resource limited settings. Current Opinion in Infectious Diseases 22:5, 455-463
    

72. 72

    Andreas H. Groll, Athanasios Tragiannidis. (2009) Recent Advances in Antifungal Prevention and Treatment. Seminars in Hematology 46:3, 212-229
    

73. 73

    Shaunna M. Huston, Christopher H. Mody. (2009) Cryptococcosis: An Emerging Respiratory Mycosis. Clinics in Chest Medicine 30:2, 253-264
    

74. 74

    Mattie Young, Sandra Macias, Derek Thomas, Floyd L. Wormley. (2009) A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins. PROTEOMICS 9:9, 2578-2588
    

75. 75

    Rhett M Shirley, John W Baddley. (2009) Cryptococcal lung disease. Current Opinion in Pulmonary Medicine 15:3, 254-260
    

76. 76

    Manjunath P Pai, Unal Sakoglu, Steven L Peterson, C Richard Lyons, Rohit Sood. (2009) Characterization of BBB permeability in a preclinical model of cryptococcal meningoencephalitis using magnetic resonance imaging. Journal of Cerebral Blood Flow &#38; Metabolism 29:3, 545-553
    

77. 77

    Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Oliver A. Cornely, Herrmann Einsele, Ruxandra Enzensberger, Holger Hebart, Werner Heinz, Christian Junghanss, Meinolf Karthaus, William Krüger, Utz Krug, Thomas Kubin, Olaf Penack, Dietmar Reichert, Stefan Reuter, Gerda Silling, Thomas Südhoff, Andrew J. Ullmann, Georg Maschmeyer. (2009) Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology 88:2, 97-110
    

78. 78

    Benjamin J Park, Kathleen A Wannemuehler, Barbara J Marston, Nelesh Govender, Peter G Pappas, Tom M Chiller. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:4, 525-530
    

79. 79

    K. L. Moore, M. J. van der Laan. (2009) Covariate adjustment in randomized trials with binary outcomes: Targeted maximum likelihood estimation. Statistics in Medicine 28:1, 39-64
    

80. 80

    S. Schwartz, E. Thiel. (2009) Cerebral aspergillosis: tissue penetration is the key. Medical Mycology 47:s1, S387-S393
    

81. 81

    Andreas H. Groll, Emmanuel Roilides, Thomas J. Walsh. Fungal infections in pediatric patients. In: Clinical Mycology. Elsevier, 2009:481-499.
    

82. 82

    Richard J. Hamill. Fungal infections of the central nervous system. In: Clinical Mycology. Elsevier, 2009:591-607.
    

83. 83

    Marianna A. Viviani, Anna Maria Tortorano. Cryptococcus. In: Clinical Mycology. Elsevier, 2009:231-249.
    

84. 84

    Michael Saccente. Fungal infections in the patient with human immunodeficiency virus infection. In: Clinical Mycology. Elsevier, 2009:417-429.
    

85. 85

    Hansong Ma, Robin C. May. Chapter 5 Virulence in Cryptococcus Species. Elsevier, 2009:131-190.
    

86. 86

    Joseph N Jarvis, Francoise Dromer, Thomas S Harrison, Olivier Lortholary. (2008) Managing cryptococcosis in the immunocompromised host. Current Opinion in Infectious Diseases 21:6, 596-603
    

87. 87

    Ignacio Gadea, José Mensa. (2008) Potencial de anidulafungina en la terapia combinada. Enfermedades Infecciosas y Microbiología Clínica 26, 51-55
    

88. 88

    Alicia Gómez-López, Oscar Zaragoza, Juan Luis Rodríguez-Tudela, Manuel Cuenca-Estrella. (2008) Pharmacotherapy of yeast infections. Expert Opinion on Pharmacotherapy 9:16, 2801-2816
    

89. 89

    Baldeep Wirk, John R. Wingard. (2008) Combination antifungal therapy: From bench to bedside. Current Infectious Disease Reports 10:6, 466-472
    

90. 90

    Derek Sloan, Sipho Dlamini, Navin Paul, Martin Dedicoat, Derek Sloan. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008.
    

91. 91

    J. W. Baddley, J. R. Perfect, R. A. Oster, R. A. Larsen, G. A. Pankey, H. Henderson, D. W. Haas, C. A. Kauffman, R. Patel, A. K. Zaas, P. G. Pappas. (2008) Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. European Journal of Clinical Microbiology & Infectious Diseases 27:10, 937-943
    

92. 92

    Brahm H. Segal, Raoul Herbrecht, David A. Stevens, Luis Ostrosky‐Zeichner, Jack Sobel, Claudio Viscoli, Thomas J. Walsh, Johan Maertens, Thomas F. Patterson, John R. Perfect, Bertrand Dupont, John R. Wingard, Thierry Calandra, Carol A. Kauffman, John R. Graybill, Lindsey R. Baden, Peter G. Pappas, John E. Bennett, Dimitrios P. Kontoyiannis, Catherine Cordonnier, Maria Anna Viviani, Jacques Bille, Nikolaos G. Almyroudis, L. Joseph Wheat, Wolfgang Graninger, Eric J. Bow, Steven M. Holland, Bart‐Jan Kullberg, William E. Dismukes, Ben E. De Pauw. (2008) Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases 47:5, 674-683
    

93. 93

    P. Dammert, B. Bustamante, E. Ticona, A. Llanos-Cuentas, L. Huaroto, V.M. Chávez, P.E. Campos. (2008) Treatment of cryptococcal meningitis in Peruvian AIDS Patients using amphotericin B and fluconazole. Journal of Infection 57:3, 260-265
    

94. 94

    Thomas J. Walsh, Dimitrios P. Kontoyiannis. (2008) Editorial Commentary: What is the Role of Combination Therapy in Management of Zygomycosis?. Clinical Infectious Diseases 47:3, 372-374
    

95. 95

    Tihana Bicanic, Robin Wood, Graeme Meintjes, Kevin Rebe, Annemarie Brouwer, Angela Loyse, Linda‐Gail Bekker, Shabbar Jaffar, Thomas Harrison. (2008) High‐Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV‐Infected Patients: A Randomized Trial. Clinical Infectious Diseases 47:1, 123-130
    

96. 96

    Pranatharthi Chandrasekar, Per T. Ljungman. (2008) Antifungal Therapy Strategies in Hematopoietic Stem-Cell Transplant Recipients: Early Treatment Options for Improving Outcomes. Transplantation 86:2, 183-191
    

97. 97

    William G. Powderly. (2008) Editorial Commentary: Dosing Amphotericin B in Cryptococcal Meningitis. Clinical Infectious Diseases 47:1, 131-132
    

98. 98

    Daniel Podzamczer. (2008) Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. Enfermedades Infecciosas y Microbiología Clínica 26:6, 356-379
    

99. 99

    K. A. Thursky, E. G. Playford, J. F. Seymour, T. C. Sorrell, D. H. Ellis, S. D. Guy, N. Gilroy, J. Chu, D. R. Shaw. (2008) Recommendations for the treatment of established fungal infections. Internal Medicine Journal 38:6b, 496-520
    

100. 100

     Andrew Kambugu, David B. Meya, Joshua Rhein, Meagan O’Brien, Edward N. Janoff, Allan R. Ronald, Moses R. Kamya, Harriet Mayanja‐Kizza, Merle A. Sande, Paul R. Bohjanen, David R. Boulware. (2008) Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 46:11, 1694-1701
     

101. 101

     L. Ostrosky-Zeichner. (2008) Combination antifungal therapy: a critical review of the evidence. Clinical Microbiology and Infection 14:s4, 65-70
     

102. 102

     Nancy Crum-Cianflone, April Truett, Mark R. Wallace. (2008) Case Report: Cryptococcal Meningitis Manifesting as a Large Abdominal Cyst in a HIV-Infected Patient with a CD4 Count Greater than 400 cells/mm ³. AIDS Patient Care and STDs 22:5, 359-363
     

103. 103

     F. Lanternier, O. Lortholary. (2008) Liposomal amphotericin B: what is its role in 2008?. Clinical Microbiology and Infection 14:s4, 71-83
     

104. 104

     John Mohr, Melissa Johnson, Travis Cooper, James S Lewis, Luis Ostrosky-Zeichner. (2008) Current Options in Antifungal Pharmacotherapy. Pharmacotherapy 28:5, 614-645
     

105. 105

     James S Lewis, John R Graybill. (2008) Fungicidal versus Fungistatic: what's in a word?. Expert Opinion on Pharmacotherapy 9:6, 927-935
     

106. 106

     Baldeep Wirk, John R. Wingard. (2008) Combination antifungal therapy: From bench to bedside. Current Fungal Infection Reports 2:1, 43-48
     

107. 107

     Andreas H. Groll, Emmanuel Roilides, Thomas J. Walsh. (2008) Pediatric pharmacology of antifungal agents. Current Fungal Infection Reports 2:1, 49-56
     

108. 108

     Read Pukkila-Worley, Eleftherios Mylonakis. (2008) Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opinion on Pharmacotherapy 9:4, 551-560
     

109. 109

     Kathleen R. Page, Richard Chaisson, Merle Sande. Cryptococcosis and other Fungal Infections (Histoplasmosis and Coccidioidomycosis) in HIV-infected Patients. In: Global HIV/AIDS Medicine. Elsevier, 2008:375-391.
     

110. 110

     Atsushi Sasakawa, Yoshihiko Yamamoto, Keishiro Yajima, Mio Sakai, Tomoko Uehira, Takuma Shirasaka, Toshio Makie. (2008) Liposomal amphotericin B for a case of intractable cryptococcal meningoencephalitis and immune reconstitution syndrome. The Journal of Medical Investigation 55:3,4, 292-296
     

111. 111

     Z. A. Kanafani, J. R. Perfect. (2008) Resistance to Antifungal Agents: Mechanisms and Clinical Impact. Clinical Infectious Diseases 46:1, 120-128
     

112. 112

     Usha Kant Misra, Jayantee Kalita, Ashok Verma. Infections of the Nervous System. In: Neurology in Clinical Practice. Elsevier, 2008:1489-1503.
     

113. 113

     Luis Ostrosky-Zeichner, John H. Rex. Antifungal and Antiviral Therapy. In: Critical Care Medicine. Elsevier, 2008:1089-1109.
     

114. 114

     Thana Khawcharoenporn, Anucha Apisarnthanarak, Linda M Mundy. (2007) Treatment of cryptococcosis in the setting of HIV coinfection. Expert Review of Anti-infective Therapy 5:6, 1019-1030
     

115. 115

     Yin Zhong Shen, Tang Kai Qi, Jian Xin Ma, Xue Yan Jiang, Jiang Rong Wang, Qing Nian Xu, Qin Huang, Xi Nian Liu, Hong Qing Sun, Hong Zhou Lu. (2007) Invasive fungal infections among inpatients with acquired immune deficiency syndrome at a Chinese university hospital. Mycoses 50:6, 475-480
     

116. 116

     John W. Baddley, Peter G. Pappas. (2007) Combination antifungal therapy for the treatment of invasive yeast and mold infections. Current Infectious Disease Reports 9:6, 448-456
     

117. 117

     Joseph N Jarvis, Thomas S Harrison. (2007) HIV-associated cryptococcal meningitis. AIDS 21:16, 2119-2129
     

118. 118

     Christine C Chiou, Thomas J Walsh, Andreas H Groll. (2007) Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy 8:15, 2465-2489
     

119. 119

     Brahm H Segal, William J Steinbach. (2007) Combination antifungals: an update. Expert Review of Anti-infective Therapy 5:5, 883-892
     

120. 120

     Shravan Kethireddy, David Andes. (2007) CNS pharmacokinetics of antifungal agents. Expert Opinion on Drug Metabolism & Toxicology 3:4, 573-581
     

121. 121

     M D Johnson, J R Perfect. (2007) Combination antifungal therapy: what can and should we expect?. Bone Marrow Transplantation 40:4, 297-306
     

122. 122

     Jhuma Sankar, Dinesh Raj, Jeeva Sankar, Pradeep K. Sharma, Rakesh Lodha, S. K. Kabra. (2007) HIV infection mimicking autoimmune disorder. The Indian Journal of Pediatrics 74:8, 777-780
     

123. 123

     Shravan Kethireddy, David Andes. (2007) CNS pharmacokinetics of antifungal agents. Expert Opinion on Drug Metabolism & Toxicology 3:4, 573-581
     

124. 124

     O. Lortholary. (2007) Management of Cryptococcal Meningitis in AIDS: The Need for Specific Studies in Developing Countries. Clinical Infectious Diseases 45:1, 81-83
     

125. 125

     Dimitrios I. Zonios, Judith Falloon, Chiung-Yu Huang, Doreen Chaitt, John E. Bennett. (2007) Cryptococcosis and Idiopathic CD4 Lymphocytopenia. Medicine 86:2, 78-92
     

126. 126

     Robert J. Baumann, Patricio S. Espinosa. Neuroepidemiology of HIV/AIDS. Elsevier, 2007:3-31.
     

127. 127

     Arthur Jackson, William G. Powderly. Cryptococcal infection. Elsevier, 2007:159-167.
     

128. 128

     J. M. Cisneros Herreros, E. Cordero Matía. (2006) Therapeutic armamentarium against systemic fungal infections. Clinical Microbiology and Infection 12:s7, 53-64
     

129. 129

     Oliver A Cornely, Jörg-Janne Vehreschild, Andrew J Ullmann. (2006) Is there a role for polyenes in treating invasive mycoses?. Current Opinion in Infectious Diseases 19:6, 565-570
     

130. 130

     Olivier Lortholary, Gwendoline Poizat, Valérie Zeller, Ségolène Neuville, André Boibieux, Muriel Alvarez, Pierre Dellamonica, Françoise Botterel, Françoise Dromer, Geneviève Chêne. (2006) Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20:17, 2183-2191
     

131. 131

     Richard J. Hamill. (2006) Editorial Commentary: Free Fluconazole for Cryptococcal Meningitis: Too Little of a Good Thing?. Clinical Infectious Diseases 43:8, 1074-1076
     

132. 132

     José G Montoya, Fernando Rosso. (2006) Is combination therapy indicated for invasive fungal infections? Yes and no. Current Opinion in Internal Medicine 5:5, 507-509
     

133. 133

     Spinello Antinori. (2006) Cryptococcosis: We Should Do Better!. Clinical Infectious Diseases 43:7, 948-949
     

134. 134

     Methee Chayakulkeeree, John R. Perfect. (2006) Cryptococcosis. Infectious Disease Clinics of North America 20:3, 507-544
     

135. 135

     Claudine Békondi, Claire Bernede, Noella Passone, Pierre Minssart, Come Kamalo, Didier Mbolidi, Yves Germani. (2006) Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. International Journal of Infectious Diseases 10:5, 387-395
     

136. 136

     Russell E Lewis. (2006) Decision Making in Antifungal Monotherapy versus Combination Therapy. Pharmacotherapy 26:6part2, 61S-67S
     

137. 137

     J I Iglesias, S H Nasr, G S Markowitz, V D D'agati. (2006) AIDS, nephrotic-range proteinuria, and renal failure. Kidney International 69:11, 2107-2110
     

138. 138

     I. Z. Ecevit, C. J. Clancy, I. M. Schmalfuss, M. H. Nguyen. (2006) The Poor Prognosis of Central Nervous System Cryptococcosis among Nonimmunosuppressed Patients: A Call for Better Disease Recognition and Evaluation of Adjuncts to Antifungal Therapy. Clinical Infectious Diseases 42:10, 1443-1447
     

139. 139

     W. E. Dismukes. (2006) Antifungal Therapy: Lessons Learned over the Past 27 Years. Clinical Infectious Diseases 42:9, 1289-1296
     

140. 140

     G. Pulido Cortijo, A. Camacho Espejo, J. Criado, A. Rivero Romn. (2006) Infecciones por hongos levaduriformes: Candida sp. y Cryptococcus sp.. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 9:57, 3693-3701
     

141. 141

     H.-Y. Sun, M.-Y. Chen, C.-F. Hsiao, S.-M. Hsieh, C.-C. Hung, S.-C. Chang. (2006) Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated with highly active anti-retroviral therapy. Clinical Microbiology and Infection 12:4, 381-388
     

142. 142

     Jerónimo Pachón, José Miguel Cisneros, Antonio Ramón Collado-Romacho, José Manuel Lomas-Cabezas, Fernando Lozano de León-Naranjo, Jorge Parra-Ruiz, Antonio Rivero-Román. (2006) Tratamiento de las infecciones fúngicas invasoras. Enfermedades Infecciosas y Microbiología Clínica 24:4, 254-263
     

143. 143

     Flucytosine. In: Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Elsevier, 2006:1388-1391.
     

144. 144

     Laura Waters, Mark Nelson. (2005) Cryptococcal disease and HIV infection. Expert Opinion on Pharmacotherapy 6:15, 2633-2644
     

145. 145

     Nina Singh, Olivier Lortholary, Barbara D. Alexander, Krishan L. Gupta, George T. John, Kenneth J. Pursell, Patricia Mu??oz, Goran B. Klintmalm, Valentina Stosor, Ramon del Busto, Ajit P. Limaye, Jyoti Somani, Marshall Lyon, Sally Houston, Andrew A. House, Timothy L. Pruett, Susan Orloff, Atul Humar, Lorraine A. Dowdy, Julia Garcia-Diaz, Andre C. Kalil, Robert A. Fisher, Joseph Heitman, Shahid Husain. (2005) Antifungal Management Practices and Evolution of Infection in Organ Transplant Recipients with Cryptococcus Neoformans Infection. Transplantation 80:8, 1033-1039
     

146. 146

     Tihana Bicanic, Robin Wood, Linda-Gail Bekker, Marta Darder, Graeme Meintjes, Thomas S Harrison. (2005) Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. The Lancet Infectious Diseases 5:9, 530-531
     

147. 147

     M. A. Fischer, W. C. Winkelmayer, R. H. Rubin, J. Avorn. (2005) The Hepatotoxicity of Antifungal Medications in Bone Marrow Transplant Recipients. Clinical Infectious Diseases 41:3, 301-307
     

148. 148

     M. Diagana, A. Millogo, B. Bouteille, P.M. Preux. (2005) Affections neurologiques en milieu tropical. EMC - Neurologie 2:3, 232-256
     

149. 149

     PT Cantey, DS Stephens, D Rimland. (2005) Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis. HIV Medicine 6:4, 253-259
     

150. 150

     I. Schedel. (2005) Neue Medikamente zur Behandlung systemischer Mykosen. Der Internist 46:6, 659-670
     

151. 151

     B. Kilani, L. Ammari, C. Marrakchi, H. Tiouiri, F. Kanoun, S. Belhaj, E. Chaker, T. Ben Chaabane. (2005) Étude rétrospective des cas de cryptococcose neuroméningée chez des patients atteints de sida à l'hôpital La Rabta à Tunis (Tunisie). Journal de Mycologie Médicale / Journal of Medical Mycology 15:2, 114-115
     

152. 152

     Ariwan Rakvit, Gary Meyerrose, Ana M. Vidal, Robert C. Kimbrough, Juan C. Sarria. (2005) Cellulitis caused by Cryptococcus neoformans in a lung transplant recipient. The Journal of Heart and Lung Transplantation 24:5, 642
     

153. 153

     Winter J Gibbs, Richard H Drew, John R Perfect. (2005) Liposomal amphotericin B: clinical experience and perspectives. Expert Review of Anti-infective Therapy 3:2, 167-181
     

154. 154

     C. A. Benson, J. E. Kaplan, H. Masur, A. Pau, K. K. Holmes. (2005) Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clinical Infectious Diseases 40:Supplement 3, S131-S235
     

155. 155

     G. P. Peter. (2005) Managing Cryptococcal Meningitis Is about Handling the Pressure. Clinical Infectious Diseases 40:3, 480-482
     

156. 156

     John W Baddley, Peter G Pappas. (2005) Antifungal Combination Therapy. Drugs 65:11, 1461-1480
     

157. 157

     Josefa Aguilar, Alfonso del Arco-Jiménez, M.ª Isabel Rodrigo, Javier de la Torre-Lima. (2005) Varón con fiebre y lesiones cutáneas. Enfermedades Infecciosas y Microbiología Clínica 23:1, 43-44
     

158. 158

     M. Diagana, A. Millogo, B. Bouteille, P.-M. Preux. (2005) Affections neurologiques en milieu tropical. EMC - Neurologie 2:1, 1-17
     

159. 159

     Jashin J. Wu, Katie R. Pang, David B. Huang, Stephen K. Tyring. (2004) Therapy of systemic fungal infections. Dermatologic Therapy 17:6, 532-538
     

160. 160

     S.G. Revankar, J. Fu, M.G. Rinaldi, S.L. Kelly, D.E. Kelly, D.C. Lamb, S.M. Keller, B.L. Wickes. (2004) Cloning and characterization of the lanosterol 14α-demethylase (ERG11) gene in Cryptococcus neoformans. Biochemical and Biophysical Research Communications 324:2, 719-728
     

161. 161

     J. D. Sobel. (2004) Combination Therapy for Invasive Mycoses: Evaluation of Past Clinical Trial Designs. Clinical Infectious Diseases 39:Supplement 4, S224-S227
     

162. 162

     J. H. Rex, J. R. Wingard, R. Wenzel, R. Herbrecht, J. Sobel, J. E. Edwards. (2004) The Design of Clinical Trials That Evaluate Antifungal Prophylaxis and Combination Therapy: Introduction and Overview. Clinical Infectious Diseases 39:Supplement 4, S165-S169
     

163. 163

     G. Maschmeyer, M. Ruhnke. (2004) Update on antifungal treatment of invasive Candida and Aspergillus infections. Derzeitiger Kenntnisstand in der antimykotischen Behandlung invasiver Candida- und Aspergillus-Infektionen. Mycoses 47:7, 263-276
     

164. 164

     Dimitrios P. Kontoyiannis, Russell E. Lewis. (2004) Toward more effective antifungal therapy: the prospects of combination therapy. British Journal of Haematology 126:2, 165-175
     

165. 165

     H.-Y. Sun, C.-C. Hung, S.-C. Chang. (2004) Management of Cryptococcal Meningitis with Extremely High Intracranial Pressure in HIV-Infected Patients. Clinical Infectious Diseases 38:12, 1790-1792
     

166. 166

     Annemarie E Brouwer, Adul Rajanuwong, Wirongrong Chierakul, George E Griffin, Robert A Larsen, Nicholas J White, Thomas S Harrison. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. The Lancet 363:9423, 1764-1767
     

167. 167

     P. Portegies, L. Solod, P. Cinque, A. Chaudhuri, J. Begovac, I. Everall, T. Weber, M. Bojar, P. Martinez-Martin, P. G. E. Kennedy. (2004) Guidelines for the diagnosis and management of neurological complications of HIV infection. European Journal of Neurology 11:5, 297-304
     

168. 168

     Nina Singh, Shahid Husain, Michael de Vera, Timothy Gayowski, Thomas V. Cacciarelli. (2004) Cryptococcus neoformans Infection in Patients With Cirrhosis, Including Liver Transplant Candidates. Medicine 83:3, 188-192
     

169. 169

     K. Angstwurm, W. Sokolowska-Koehler, C. Stadelmann, E. Schielke, J. R. Weber. (2004) Fulminant cryptococcal meningitis as presenting feature in a patient with AIDS. European Journal of Neurology 11:5, 353-354
     

170. 170

     David A. Stevens. (2004) Azoles in the Management of Systemic Fungal Infections. Infectious Diseases in Clinical Practice 12:2, 81-92
     

171. 171

     J. R. Azanza Perea, B. Sadaba Diaz de Rada, E. Garcia Quetglas, M. J. Munoz Juarez. (2004) Oral versus intravenous therapy in the treatment of systemic mycosis. Clinical Microbiology and Infection 10:s1, 96-106
     

172. 172

     Fran??oise Dromer, Simone Mathoulin-P??lissier, Arnaud Fontanet, Olivier Ronin, Bertrand Dupont, Olivier Lortholary. (2004) Epidemiology of HIV-associated cryptococcosis in France (1985???2001). AIDS 18:3, 555-562
     

173. 173

     Duangchit Panomvana Na Ayudhya, Nawarat Thanompuangseree, Somsit Tansuphaswadikul. (2004) Effect of Rifampicin on the Pharmacokinetics of Fluconazole in Patients with AIDS. Clinical Pharmacokinetics 43:11, 725-732
     

174. 174

     Markus Ruhnke. (2004) Mucosal and Systemic Fungal Infections in Patients with AIDS. Drugs 64:11, 1163-1180
     

175. 175

     Françoise Dromer, Olivier Lortholary. (2004) Cryptococcose. EMC - Maladies infectieuses 1:1, 1-10
     

176. 176

     Nigar Kirmani, William G. Powderly. Gender-Specific Issues in Fungal Infections. In: Principles of Gender-Specific Medicine. Elsevier, 2004:910-922.
     

177. 177

     Nina Singh. (2003) Treatment of opportunistic mycoses: how long is long enough?. The Lancet Infectious Diseases 3:11, 703-708
     

178. 178

     Dimitrios P. Kontoyiannis, Russell E. Lewis. (2003) Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resistance Updates 6:5, 257-269
     

179. 179

     Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Meinolf Karthaus, Hermann Einsele, Stefan Guth, Gudrun Heussel, Claus-Peter Heussel, Christian Junghanss, Winfried K. Kern, Thomas Kubin, Georg Maschmeyer, Orhan Sezer, Gerda Silling, Thomas Südhoff, Hubert Szelényi†, Andrew J. Ullmann. (2003) Treatment of fungal infections in hematology and oncology. Annals of Hematology 82:S2, S133-S140
     

180. 180

     Joseph M Bliss, Melanie Wellington, Francis Gigliotti. (2003) Antifungal pharmacotherapy for neonatal candidiasis. Seminars in Perinatology 27:5, 365-374
     

181. 181

     David W Denning. (2003) Echinocandin antifungal drugs. The Lancet 362:9390, 1142-1151
     

182. 182

     I. Lutsar, S. Roffey, P. Troke. (2003) Voriconazole Concentrations in the Cerebrospinal Fluid and Brain Tissue of Guinea Pigs and Immunocompromised Patients. Clinical Infectious Diseases 37:5, 728-732
     

183. 183

     Antonella Lupetti, Peter H. Nibbering, Mario Campa, Mario Del Tacca, Romano Danesi. (2003) Molecular targeted treatments for fungal infections: the role of drug combinations. Trends in Molecular Medicine 9:6, 269-276
     

184. 184

     Thomas F. Patterson. (2003) Combination antifungal therapy. The Pediatric Infectious Disease Journal 22:6, 555-556
     

185. 185

     Asda Vibhagool, Somnuek Sungkanuparph, Piroon Mootsikapun, Ploenchan Chetchotisakd, Somsit Tansuphaswaswadikul, Chureeratana Bowonwatanuwong, Atiporn Ingsathit. (2003) Discontinuation of Secondary Prophylaxis for Cryptococcal Meningitis in Human Immunodeficiency Virus–Infected Patients Treated with Highly Active Antiretroviral Therapy: A Prospective, Multicenter, Randomized Study. Clinical Infectious Diseases 36:10, 1329-1331
     

186. 186

     Michael Saccente, Richard W. McDonnell, Larry M. Baddour, M. Jane Mathis, Robert W. Bradsher. (2003) Cerebral Histoplasmosis in the Azole Era: Report of Four Cases and Review. Southern Medical Journal 96:4, 410-416
     

187. 187

     David W Denning, Christopher C Kibbler, Rosemary A Barnes. (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. The Lancet Infectious Diseases 3:4, 230-240
     

188. 188

     D.P. Kontoyiannis, E. Mantadakis, G. Samonis. (2003) Systemic mycoses in the immunocompromised host: an update in antifungal therapy. Journal of Hospital Infection 53:4, 243-258
     

189. 189

     Andreas H Groll, Juan C Gea-Banacloche, Axel Glasmacher, Gudrun Just-Nuebling, Georg Maschmeyer, Thomas J Walsh. (2003) Clinical pharmacology of antifungal compounds. Infectious Disease Clinics of North America 17:1, 159-191
     

190. 190

     Harold W. Horowitz, Gary P. Wormser. Care of the Adult Patient with HIV Infection. In: AIDS and Other Manifestations of HIV Infection. Elsevier, 2003:305-370.
     

191. 191

     Hadi Manji, Roberto Guiloff. Human Immunodeficiency Virus Infections—Neurological Manifestations. In: Neurological Disorders. Elsevier, 2003:623-646.
     

192. 192

     Carlos Lumbreras, Manuel Lizasoain, José María Aguado. (2003) Antifúngicos de uso sistémico. Enfermedades Infecciosas y Microbiología Clínica 21:7, 366-380
     

193. 193

     Joan Gavaldà, Isabel Ruiz. (2003) Recomendaciones para el tratamiento de la infección fúngica invasiva. Infeccion fúngica invasiva por Candida spp.. Enfermedades Infecciosas y Microbiología Clínica 21:9, 498-508
     

194. 194

     J.A. Girón González, F. Brun Romero, A. Arizcorreta Yarza. (2003) Complicaciones neurológicas de la infección por VIH. Medicine - Programa de Formación Médica Continuada Acreditado 8:97, 5247-5253
     

195. 195

     John R Perfect, Arturo Casadevall. (2002) Cryptococcosis. Infectious Disease Clinics of North America 16:4, 837-874
     

196. 196

     Liang Zhang, Yan Zhang, Yiming Zhou, Yanjun Zhao, Yuxiang Zhou, Jing Cheng. (2002) Expression profiling of the response of Saccharomyces cerevisiae to 5-fluorocytosine using a DNA microarray. International Journal of Antimicrobial Agents 20:6, 444-450
     

197. 197

     Brahm H Segal, Eric J Bow, Francisco Menichetti. (2002) Fungal infections in nontransplant patients with hematologic malignancies. Infectious Disease Clinics of North America 16:4, 935-964
     

198. 198

     Stuart J. Pocock, Susan E. Assmann, Laura E. Enos, Linda E. Kasten. (2002) Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems. Statistics in Medicine 21:19, 2917-2930
     

199. 199

     Kimberly J. Gambarin, Richard J. Hamill. (2002) Management of increased intracranial pressure in cryptococcal meningitis. Current Infectious Disease Reports 4:4, 332-338
     

200. 200

     C. Tascini, S. Ferranti, G. Gemignani, F. Messina, F. Menichetti. (2002) Clinical microbiological case: fever and headache in a heavy consumer of eucalyptus extract. Clinical Microbiology and Infection 8:7, 445-446
     

201. 201

     Rafik Samuel, Robert L. Bettiker, Byungse Suh. (2002) AIDS related opportunistic infections, going but not gone. Archives of Pharmacal Research 25:3, 215-228
     

202. 202

     Kent A. Sepkowitz. (2002) Opportunistic Infections in Patients with and Patients without Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases 34:8, 1098-1107
     

203. 203

     Annemarie Polak. (2002) Flucytosin - ein klassischer Kombinationspartner. Mycoses 45:S3, 31-33
     

204. 204

     Li-Ping Zhu, Yao-Zhong Shi, Xin-Hua Weng, F.M.C. Muller. (2002) Case Reports. Pulmonary Cryptococcosis associated with Cryptococcal Meningitis in non-AIDS Patients. Mycoses 45:3-4, 111-117
     

205. 205

     Eleftherios Mylonakis, Francisco Marty. (2002) Antifungal use in HIV infection. Expert Opinion on Pharmacotherapy 3:2, 91-102
     

206. 206

     A. S. Kantarcioglu, A. Yücel. (2002) A flucytosine-resistant Cryptococcus neoformans (serotype D) strain isolated in Turkey from cutaneous lesions. Medical Mycology 40:5, 519-523
     

207. 207

     Alfonso del Arco, José Luis Prada, Javier de la Torre, Lourdes Romualdo. (2002) Desensibilización en paciente con hipersensibilidad a fluconazol e infección por el virus de la inmunodeficiencia humana. Medicina Clínica 119:2, 77
     

208. 208

     P. Pitisuttithum, S. Tansuphasawadikul, A.J.H. Simpson, P.A. Howe, N.J. White. (2001) A Prospective Study of AIDS-associated Cryptococcal Meningitis in Thailand Treated with High-dose Amphotericin B. Journal of Infection 43:4, 226-233
     

209. 209

     Douglas J. Keele, Veronica C. DeLallo, Russell E. Lewis, Erika J. Ernst, Michael E. Klepser. (2001) Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagnostic Microbiology and Infectious Disease 41:3, 121-126
     

210. 210

     Lourdes Irizarry. (2001) Cryptococcal meningitis. Current Treatment Options in Neurology 3:5, 413-426
     

211. 211

     Peter G. Pappas, John R. Perfect, Gretchen A. Cloud, Robert A. Larsen, George A. Pankey, Daniel J. Lancaster, Harold Henderson, Carol A. Kauffman, David W. Haas, Michael Saccente, Richard J. Hamill, Melissa S. Holloway, Robert M. Warren, William E. Dismukes. (2001) Cryptococcosis in Human Immunodeficiency Virus–Negative Patients in the Era of Effective Azole Therapy. Clinical Infectious Diseases 33:5, 690-699
     

212. 212

     Michael E. Klepser. (2001) Antifungal Resistance Among Candida Species. Pharmacotherapy 21:8 Part 2, 124S-132S
     

213. 213

     William G Powderly, Anucha Apisarnthanarak. (2001) Treatment of acute cryptococcal disease. Expert Opinion on Pharmacotherapy 2:8, 1259-1268
     

214. 214

     Russell E. Lewis, Dimitrios P. Kontoyiannis. (2001) Rationale for Combination Antifungal Therapy. Pharmacotherapy 21:8 Part 2, 149S-164S
     

215. 215

     Peter G. Pappas. (2001) Therapy of cryptococcal meningitis in non-HIV-infected patients. Current Infectious Disease Reports 3:4, 365-370
     

216. 216

     John H. Rex, Thomas J. Walsh, Mary Nettleman, Elias J. Anaissie, John E. Bennett, Eric J. Bow, A. J. Carillo‐Munoz, Pascal Chavanet, Gretchen A. Cloud, David W. Denning, Ben E. de Pauw, John E. Edwards Jr., John W. Hiemenz, Carol A. Kauffman, Gabriel Lopez‐Berestein, Pietro Martino, Jack D. Sobel, David A. Stevens, Richard Sylvester, Jan Tollemar, Claudio Viscoli, Maria A. Viviani, Teresa Wu. (2001) Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses. Clinical Infectious Diseases 33:1, 95-106
     

217. 217

     Paul E. Sax. (2001) OPPORTUNISTIC INFECTIONS IN HIV DISEASE: DOWN BUT NOT OUT. Infectious Disease Clinics of North America 15:2, 433-455
     

218. 218

     E Andrès, M Tiphine, V Letscher-Bru, R Herbrecht. (2001) Nouvelles formes lipidiques de l’amphotéricine B. Revue de la littérature. La Revue de Médecine Interne 22:2, 141-150
     

219. 219

     A. Velegraki, V. G. Kiosses, H. Pitsouni, D. Toukas, V. D. Daniilidis, N. J. Legakis. (2001) First report of Cryptococcus neoformans var. gattii serotype B from Greece. Medical Mycology 39:5, 419-422
     

220. 220

     Marc Boogaerts, Johan Maertens. (2001) Clinical Experience with Itraconazole in Systemic Fungal Infections. Drugs 61:Supplement 1, 39-47
     

221. 221

     Rajiv S. Bhatnagar, Kaveh Ashrafi, Klaus Fütterer, Gabriel Waksman, Jeffrey I. Gordon. 9 Biology and enzymology of protein N-myristoylation. Elsevier, 2001:241-290.
     

222. 222

     Cynthia M. Hingtgen, Karen L. Roos. Chapter 12 Clinical Trials in Central Nervous System Infections. Elsevier, 2001:237-259.
     

223. 223

     Daniel Podzamczer, José Ramón Arribas, José Mallolas, José María Peña, Federico Pulidod, Koldo Aguirrebengoa, Carlos Barros, Rosa Blazquez, José Ramón Costa, Fernando Dronda, Javier Ena, Antonio Guerrero, Félix Gutiérrez, Javier Juega, Pablo Labarga, Jaime Locutura, José López Aldeguer, Santiago Moreno, Arturo Noguerado, Imma Ocaña, Belén Padilla, Elisa Pérez-Cecilia, Ma Jesús Pérez Elías, Joaquín Portilla, Antonio Rivero, Victor Roca. (2001) Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretrovírico de gran actividad. Enfermedades Infecciosas y Microbiología Clínica 19:8, 376-392
     

224. 224

     John R. Graybill. (2000) The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resistance Updates 3:6, 364-383
     

225. 225

     Elizabeth S. Dodds, Richard H. Drew, John R. Perfect. (2000) Antifungal Pharmacodynamics: Review of the Literature and Clinical Applications. Pharmacotherapy 20:11, 1335-1355
     

226. 226

     P. K. Coyle. (2000) Chronic meningitis. Current Treatment Options in Neurology 2:4, 375-387
     

227. 227

     P PATEL, J RAMANATHAN, M KAYSER, J BARANJR. (2000) Primary cutaneous cryptococcosis of the nose in an immunocompetent woman. Journal of the American Academy of Dermatology 43:2, 344-345
     

228. 228

     Thomas F Patterson, William R Kirkpatrick, Mary White, John W Hiemenz, John R Wingard, Bertrand Dupont, Michael G Rinaldi, David A Stevens, John R Graybill. (2000) Invasive Aspergillosis. Medicine 79:4, 250-260
     

229. 229

     William G. Powderly. (2000) Cryptococcal meningitis in HIV-infected patients. Current Infectious Disease Reports 2:4, 352-357
     

230. 230

     W.G Powderly. (2000) Current Approach to the Acute Management of Cryptococcal Infections. Journal of Infection 41:1, 18-22
     

231. 231

     W. E. Dismukes. (2000) Introduction to Antifungal Drugs. Clinical Infectious Diseases 30:4, 653-657
     

232. 232

     M. S. Saag, R. J. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. Powderly, J. D. Sobel, W. E. Dismukes, . (2000) Practice Guidelines for the Management of Cryptococcal Disease. Clinical Infectious Diseases 30:4, 710-718
     

233. 233

     Susan F Assmann, Stuart J Pocock, Laura E Enos, Linda E Kasten. (2000) Subgroup analysis and other (mis)uses of baseline data in clinical trials. The Lancet 355:9209, 1064-1069
     

234. 234

     Russell E Lewis, Michael E Klepser, Michael A Pfaller. (2000) In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagnostic Microbiology and Infectious Disease 36:2, 101-105
     

235. 235

     Kirk Miller, Henry Masur. Management of Opportunistic Infections. In: AIDS-Related Cancers and Their Treatment. CRC Press, 2000:331-369.
     

236. 236

     L. Rodero, S. Cordoba, P. Cahn, M. Soria, M. Lucarini, G. Davel, S. Kaufman, C. Canteros, L. Guelfand. (2000) Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Medical Mycology 38:3, 201-207
     

237. 237

     J. R. Graybill, J. Sobel, M. Saag, C. van der Horst, W. Powderly, G. Cloud, L. Riser, R. Hamill, W. Dismukes, . (2000) Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis. Clinical Infectious Diseases 30:1, 47-54
     

238. 238

     Jack D. Sobel. (2000) Use of Antifungal Drugs in Pregnancy. Drug Safety 23:1, 77-85
     

239. 239

     M. Tiphine, V. Letscher-Bru, R. Herbrecht. (1999) Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transplant Infectious Disease 1:4, 273-283
     

240. 240

     Larry E. Davis. (1999) FUNGAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM. Neurologic Clinics 17:4, 761-781
     

241. 241

     Fausto Lalla, Giampietro Pellizzer, Vinicio Manfrin, Paolo Benedetti, Marzia Franzetti, Roberto Nicolin, Alberto Vaglia. (1999) Maintenance therapy for cryptococcosis in patients with AIDS after successful primary therapy: oral fluconazole (300 mg daily) versus oral itraconazole (300 mg daily). Clinical Microbiology and Infection 5:9, 567-570
     

242. 242

     John R. Perfect, Gary M. Cox. (1999) Drug resistance in Cryptococcus neoformans. Drug Resistance Updates 2:4, 259-269
     

243. 243

     V. T. Andriole. (1999) Current and future antifungal therapy: new targets for antifungal agents. Journal of Antimicrobial Chemotherapy 44:2, 151-162
     

244. 244

     Annemarie Polak. (1999) <tocheading>Review Article</tocheading>. Mycoses 42:5-6, 355-370
     

245. 245

     Eleftherios Mylonakis, Nathan A Merriman, Josiah D Rich, Timothy P Flanigan, Beverly C Walters, Karen T Tashima, Maria D Mileno, Charles M van der Horst. (1999) Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis. Diagnostic Microbiology and Infectious Disease 34:2, 111-114
     

246. 246

     Allan R. Tunkel. (1999) Chronic meningitis. Current Infectious Disease Reports 1:2, 160-165
     

247. 247

     O. LORTHOLARY, L. IMPROVISI, M. NICOLAS, F. PROVOST, B. DUPONT, F. DROMER. (1999) Fungemia during murine cryptococcosis sheds some light on pathophysiology 1. Medical Mycology 37:3, 169-174
     

248. 248

     O. LORTHOLARY 2, L. IMPROVISI, M. NICOLAS, F. PROVOST, B. DUPONT, F. DROMER. (1999) Fungemia during murine cryptococcosis sheds some light on pathophysiology 1. Medical Mycology 37:3, 169-174
     

249. 249

     Thomas Lehrnbecher, Andreas H. Groll, Stephen J. Chanock. (1999) Treatment of fungal infections in neutropenic children. Current Opinion in Pediatrics 11:1, 39-46
     

250. 250

     O. LORTHOLARY, L. IMPROVISI, M. NICOLAS, F. PROVOST, B. DUPONT, F. DROMER. (1999) Fungemia during murine cryptococcosis sheds some light on pathophysiology. Medical Mycology 37:3, 169-174
     

251. 251

     C L Terrell. (1999) Antifungal agents. Part II. The azoles.. Mayo Clinic Proceedings 74:1, 78-100
     

252. 252

     Robert G. Irwin, Andreas H. Groll, Thomas J. Walsh. Antifungal drugs. Elsevier, 1999:285-301.
     

253. 253

     R Patel. (1998) Antifungal agents. Part I. Amphotericin B preparations and flucytosine.. Mayo Clinic Proceedings 73:12, 1205-1225
     

254. 254

     M. Pfaller, J. Zhang, S. Messer, M. Tumberland, E. Mbidde, C. Jessup, M. Ghannoum. (1998) Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. Diagnostic Microbiology and Infectious Disease 32:3, 191-199
     

255. 255

     Amy A. Pruitt. (1998) INFECTIONS OF THE NERVOUS SYSTEM. Neurologic Clinics 16:2, 419-447
     

256. 256

     Alan M. Sugar. (1998) Antifungal combination therapy: where we stand. Drug Resistance Updates 1:2, 89-92
     

257. 257

     Andreas H. Groll, Stephen C. Piscitelli, Thomas J. Walsh. Clinical Pharmacology of Systemic Antifungal Agents:A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development. Elsevier, 1998:343-500.
     

258. 258

     (1997) Treatment of Cryptococcal Meningitis. New England Journal of Medicine 337:21, 1557-1558
     Free Full Text

Letters